Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.
J Clin Pharm Ther
; 41(3): 360-361, 2016 Jun.
Article
en En
| MEDLINE
| ID: mdl-27009771
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. CASE DESCRIPTION The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. WHAT IS NEW ANDCONCLUSION:
Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
J Clin Pharm Ther
Asunto de la revista:
FARMACIA
/
TERAPEUTICA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Francia